Chronic IL-33 expression predisposes to viral-induced exacerbations of asthma by increasing type-2 inflammation and dampening antiviral immunity

Using a preclinical model of chronic asthma and primary human AECs we show that anti-IL-33 boosted IFNs and lowered RV replication, suggesting that in addition to attenuating type-2 inflammation, anti-IL-33 therapy may enhance host defence.

http://ift.tt/2jRhfGZ